Trial Profile
A Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Ascending Doses of GSK2018682 (S1P1 Agonist) in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2023
Price :
$35
*
At a glance
- Drugs GSK 2018682 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 15 Sep 2011 New trial record